Susquehanna Fundamental Investments LLC Takes $209,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Susquehanna Fundamental Investments LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,000 shares of the biopharmaceutical company’s stock, valued at approximately $209,000.

A number of other institutional investors have also added to or reduced their stakes in HALO. Rise Advisors LLC bought a new position in shares of Halozyme Therapeutics during the 1st quarter worth approximately $25,000. Whittier Trust Co. bought a new stake in Halozyme Therapeutics during the first quarter worth $27,000. GAMMA Investing LLC boosted its position in Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 254 shares during the last quarter. International Assets Investment Management LLC bought a new position in Halozyme Therapeutics in the 2nd quarter valued at $33,000. Finally, Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at $49,000. 97.79% of the stock is owned by institutional investors.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the sale, the chief executive officer now owns 676,744 shares of the company’s stock, valued at approximately $40,063,244.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Nicole Labrosse sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, July 22nd. The stock was sold at an average price of $53.93, for a total transaction of $269,650.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares in the company, valued at approximately $834,836.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total transaction of $592,000.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares in the company, valued at approximately $40,063,244.80. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 84,881 shares of company stock valued at $4,932,284. 2.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on HALO shares. The Goldman Sachs Group boosted their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a report on Monday, July 22nd. Wells Fargo & Company boosted their target price on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, June 7th. Benchmark restated a “buy” rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $65.00 price objective on shares of Halozyme Therapeutics in a research note on Friday. Finally, Piper Sandler downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their target price for the stock from $48.00 to $51.00 in a research report on Friday, June 7th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Halozyme Therapeutics Stock Down 2.1 %

Halozyme Therapeutics stock opened at $59.18 on Friday. The firm has a 50 day simple moving average of $58.96 and a 200 day simple moving average of $50.28. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19. Halozyme Therapeutics, Inc. has a 1-year low of $32.83 and a 1-year high of $65.53. The firm has a market capitalization of $7.53 billion, a price-to-earnings ratio of 24.45, a P/E/G ratio of 0.56 and a beta of 1.27.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.18. The company had revenue of $231.40 million during the quarter, compared to analysts’ expectations of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.68 earnings per share. On average, analysts predict that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.